Oramorph sr and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Oramorph sr (morphine sulfate), especially for people who are male, 60+ old, also take Acetaminophen, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Oramorph sr. It is created by eHealthMe based on reports of 2,797 people who have side effects when taking Oramorph sr from the FDA, and is updated regularly.

What is Oramorph sr?

Oramorph sr has active ingredients of morphine sulfate. It is often used in pain. eHealthMe is studying from 2,897 Oramorph sr users. Check the latest studies of Oramorph sr.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,067 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

2,797 people reported to have side effects when taking Oramorph sr.
Among them, 26 people (0.93%) have Neoplasm progression.

Could Oramorph sr cause Neoplasm progression?

Among these 26 people:

What is the gender of people who have Neoplasm progression when taking Oramorph sr? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Neoplasm progression when taking Oramorph sr? *

What are other drugs people take besides Oramorph sr? *

Acetaminophen: 15 people, 57.69%
Morphine: 13 people, 50.00%
Lorazepam: 10 people, 38.46%
Olanzapine: 10 people, 38.46%
Ranitidine: 9 people, 34.62%
Gentamicin: 9 people, 34.62%
Clozaril: 9 people, 34.62%
Chlorpheniramine Maleate: 9 people, 34.62%
Levofloxacin: 9 people, 34.62%
Mirtazapine: 9 people, 34.62%

What are other side effects people have besides Neoplasm progression? *

Nausea (feeling of having an urge to vomit): 14 people, 53.85%
Thrombocytopenia (decrease of platelets in blood): 12 people, 46.15%
Fatigue (feeling of tiredness): 11 people, 42.31%
Diarrhea: 10 people, 38.46%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 10 people, 38.46%
Hair Loss: 10 people, 38.46%
Lymphocyte Count Decreased: 9 people, 34.62%
Neuropathy Peripheral (surface nerve damage): 9 people, 34.62%
Neutrophil Count Increased (excess than normal number of neutrophil a type of blood cell): 9 people, 34.62%
Mucosal Inflammation (infection of mucous membrane): 9 people, 34.62%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 13 people, 50.00%
Breast Cancer Metastatic: 13 people, 50.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 34.62%
Febrile Neutropenia (fever with reduced white blood cells): 9 people, 34.62%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 9 people, 34.62%
Bone Pain: 4 people, 15.38%
High Blood Pressure: 4 people, 15.38%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 11.54%
Renal Cell Carcinoma (a kidney cancer): 2 people, 7.69%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Oramorph sr and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oramorph sr:

Oramorph sr (2,897 reports)

Browse all side effects of Oramorph sr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,067 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

Related publications that referenced our studies

Rasmy A, Rahal M, Kisana M, Ahmad S, Salah A, "Morphine induced thrombocytopenia: A case report", Journal of Case Reports and Images in Oncology, 2015 Dec .
Rasmy A, Rahal M, Kisana M, Ahmad S, Salah A, "Morphine induced thrombocytopenia: A case report", Journal of Case Reports and Images in Oncology, 2015 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on morphine sulfate (the active ingredients of Oramorph sr) and Oramorph sr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.